Targeting MET in cancer therapy
- Author:
Mo HONG-NAN
1
;
Liu PENG
1
Author Information
1. Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
Proto-oncogene protein c-MET;
Antineoplastic agents;
Protein kinase inhibitors;
Molecular targeted therapy
- From:
Chronic Diseases and Translational Medicine
2017;3(3):148-153
- CountryChina
- Language:English
-
Abstract:
MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. MET exon 14 alterations and MET gene amplification play a critical role in the origin of cancer. Several monoclonal antibodies and small-molecule inhibitors of c-MET have been evaluated in clinical trials. In patients with advanced non-small cell lung cancer, cabozantinib and crizotinib showed clear efficacy with a generally tolerable adverse events profile. In gastrointestinal cancers, most phase Ⅲ trials of MET inhibitors showed negative results. In hepatocellular carcinoma, based on the encouraging results of some phase Ⅱ studies, a series of phase Ⅲ trials are currently recruiting patients to access the efficacy and safety of MET inhibitors.
